cardiometabolic diseases

Showing 1 posts of 1 posts found.

Eli Lilly to acquire Versanis Bio for $1.9bn

July 17, 2023
Sales and Marketing Cardiology, Eli Lilly, Versanis Bio, acquisition, cardiometabolic diseases

Eli Lilly and Versanis Bio have announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company …

Latest content